IgG Antibody Response Elicited by a Fully Synthetic Two-Component Carbohydrate-Based Cancer Vaccine Candidate with α-Galactosylceramide as Built-in Adjuvant

Xu-Guang Yin; Xiang-Zhao Chen; Wen-Mei Sun; Xiao-Shan Geng; Xiao-Kang Zhang; Jian Wang; Pan-Pan Ji; Zhong-Yin Zhou; Dong Jae Baek; Guang-Fu Yang; Zheng Liu; Jun Guo

doi:10.1021/acs.orglett.6b03591

IgG Antibody Response Elicited by a Fully Synthetic Two-Component Carbohydrate-Based Cancer Vaccine Candidate with α-Galactosylceramide as Built-in Adjuvant

Org Lett. 2017 Feb 3;19(3):456-459. doi: 10.1021/acs.orglett.6b03591. Epub 2017 Jan 25.

Authors

Affiliations

¹ Key Laboratory of Pesticide & Chemical Biology of Ministry of Education, College of Chemistry, Central China Normal University , 152 Luoyu Road, Wuhan, Hubei 430079, P. R. China.
² Department of Gastroenterology, Renmin Hospital of Wuhan University , Wuhan, Hubei 430060, P. R. China.
³ College of Pharmacy, Natural Medicine Research Institute, Mokpo National University , 1666 Youngsan-ro, Muan-gun, Jeonnam 534-729, Korea.

PMID: 28121454
DOI: 10.1021/acs.orglett.6b03591

Abstract

A fully synthetic self-adjuvanting cancer vaccine candidate was constructed through covalent conjugation of invariant natural killer T (iNKT) cell ligand α-galactosylceramide (αGalCer) with sialyl Tn (STn), a representative tumor-associated carbohydrate antigen (TACA). This two-component vaccine STn-αGalCer is devoid of antigenic peptide, featuring the well-defined structure with high simplicity. STn-αGalCer showed remarkable efficacy in inducing antibody class switching from IgM to STn-specific IgG. Subtypes of IgG antibody were primarily IgG1 and IgG3.

Publication types

Research Support, Non-U.S. Gov't